This trial shows that for some types of cancer, a new immunotherapy drug can help to fight the disease even after the tumor has grown.
1 Primary · 6 Secondary · Reporting Duration: Study treatment will continue until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment for any other reason up to 48 months.
29 Total Participants · 1 Treatment Group
Primary Treatment: Axitinib · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: